KalVista Pharmaceuticals Sees Unusually High Options Volume (NASDAQ:KALV)

KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) was the recipient of some unusual options trading on Friday. Stock traders purchased 5,072 call options on the company. This is an increase of approximately 569% compared to the average daily volume of 758 call options.

Key Headlines Impacting KalVista Pharmaceuticals

Here are the key news stories impacting KalVista Pharmaceuticals this week:

• Positive Sentiment: Stifel Nicolaus raised its price target to $42 and reiterated a “buy” rating, signaling significant upside versus the current share price. Stifel Price Target Raise
• Positive Sentiment: Needham & Company increased its price target to $36 and maintained a “buy” rating, adding to analyst momentum behind the stock. Needham Price Target Raise
• Positive Sentiment: Company reported a strong commercial start for EKTERLY, posting $49.1M in EKTERLY revenue during an eight‑month transition period — a tangible revenue data point supporting the bull case. EKTERLY Revenue Report
• Positive Sentiment: Unusually large options activity: traders bought 5,072 KALV call options (≈569% above normal call volume), indicating speculative or hedged bullish positioning by options market participants.
• Positive Sentiment: Stock hit a new 52‑week high following analyst upgrades, reinforcing momentum and attracting technical buyers. 52‑Week High / Analyst Upgrade
• Neutral Sentiment: Citizens Jmp trimmed its price target slightly from $29 to $28 but kept a “market outperform” rating — a modest mixed signal compared with other, larger raises. Citizens Jmp Note
• Neutral Sentiment: Recent earnings/earnings‑call transcripts and summaries (Q4/8‑month and Q1 2025 materials) are available for deeper review; these provide context on commercial rollout, margins and guidance but contain no single surprise that would alone explain the move. Q1 2025 Call Summary 8‑Month Transcript

Analysts Set New Price Targets

A number of equities analysts recently commented on KALV shares. Weiss Ratings restated a “sell (d-)” rating on shares of KalVista Pharmaceuticals in a report on Thursday, January 22nd. HC Wainwright boosted their target price on shares of KalVista Pharmaceuticals from $27.00 to $37.00 and gave the stock a “buy” rating in a research report on Friday, January 9th. Wall Street Zen upgraded shares of KalVista Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Saturday, December 6th. TD Cowen restated a “buy” rating on shares of KalVista Pharmaceuticals in a report on Wednesday, December 3rd. Finally, Needham & Company LLC lifted their price objective on shares of KalVista Pharmaceuticals from $35.00 to $36.00 and gave the company a “buy” rating in a research note on Wednesday. Seven equities research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, KalVista Pharmaceuticals currently has a consensus rating of “Moderate Buy” and a consensus price target of $32.60.

KalVista Pharmaceuticals Stock Performance

Shares of NASDAQ KALV traded up $0.19 during trading hours on Friday, hitting $19.14. 856,055 shares of the company’s stock were exchanged, compared to its average volume of 1,026,048. The company’s 50-day moving average price is $15.95 and its 200-day moving average price is $14.44. KalVista Pharmaceuticals has a 1-year low of $9.23 and a 1-year high of $19.95. The stock has a market capitalization of $967.32 million, a price-to-earnings ratio of -4.85 and a beta of -0.35. The company has a debt-to-equity ratio of 8.18, a current ratio of 7.22 and a quick ratio of 7.21.

Insider Transactions at KalVista Pharmaceuticals

In other KalVista Pharmaceuticals news, insider Nicole Sweeny sold 3,975 shares of the business’s stock in a transaction dated Monday, February 23rd. The stock was sold at an average price of $15.57, for a total value of $61,890.75. Following the transaction, the insider owned 47,003 shares in the company, valued at $731,836.71. The trade was a 7.80% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, CFO Brian Piekos sold 1,767 shares of the company’s stock in a transaction dated Monday, February 23rd. The stock was sold at an average price of $15.57, for a total value of $27,512.19. Following the completion of the transaction, the chief financial officer directly owned 13,762 shares in the company, valued at approximately $214,274.34. The trade was a 11.38% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last three months, insiders have sold 33,378 shares of company stock worth $522,290. 4.30% of the stock is owned by company insiders.

Institutional Investors Weigh In On KalVista Pharmaceuticals

Several hedge funds have recently modified their holdings of KALV. AQR Capital Management LLC bought a new position in KalVista Pharmaceuticals during the first quarter worth $646,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its holdings in KalVista Pharmaceuticals by 13.7% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 24,325 shares of the specialty pharmaceutical company’s stock valued at $281,000 after purchasing an additional 2,939 shares during the period. Goldman Sachs Group Inc. boosted its holdings in KalVista Pharmaceuticals by 3.7% in the 1st quarter. Goldman Sachs Group Inc. now owns 339,936 shares of the specialty pharmaceutical company’s stock valued at $3,923,000 after purchasing an additional 12,263 shares during the period. Geode Capital Management LLC grew its position in KalVista Pharmaceuticals by 2.8% in the 2nd quarter. Geode Capital Management LLC now owns 941,212 shares of the specialty pharmaceutical company’s stock worth $10,642,000 after purchasing an additional 25,971 shares during the last quarter. Finally, Police & Firemen s Retirement System of New Jersey grew its position in KalVista Pharmaceuticals by 26.8% in the 2nd quarter. Police & Firemen s Retirement System of New Jersey now owns 9,756 shares of the specialty pharmaceutical company’s stock worth $110,000 after purchasing an additional 2,061 shares during the last quarter.

KalVista Pharmaceuticals Company Profile

KalVista Pharmaceuticals is a clinical‐stage biotechnology company focused on the discovery and development of small‐molecule protease inhibitors for orphan and specialty disease indications. The firm’s scientific platform centers on selective inhibition of plasma kallikrein, a serine protease implicated in disorders characterized by vascular leak, edema and inflammation. KalVista’s approach leverages oral and intravitreal delivery formats to target both systemic and ophthalmic conditions.

The company’s lead programs include an oral plasma kallikrein inhibitor in clinical trials for the acute treatment of hereditary angioedema (HAE) attacks and an intravitreal kallikrein inhibitor being evaluated for diabetic macular edema.